

CALL FOR MEMBERS

PCSK9 Education and Research Forum

New, independent, not-for-profit initiative

On behalf of the Executive Editorial Board and our Editorial Advisory Board we would like to invite Israeli Atherosclerosis Society to join us in a new initiative in the prevention of atherosclerosis and cardiovascular disease, the *PCSK9 Education and Research Forum* www.pcsk9forum.org.

The Forum was recently established as a not-for-profit scientific organisation registered in the UK to foster education and research focussed on PCSK9, an exciting target in emerging strategies for management of atherogenic dyslipidaemias. The Forum aims to expand awareness and knowledge of the significant role played by PCSK9 in lipid and cholesterol metabolism and its value as a novel therapeutic target.

As you are aware, PCSK9 is a key example of translational medicine. Within a decade, identification of mutations in the PCSK9 gene has driven emerging PCSK9 science and the development of novel therapies targeting PCSK9. Clinical studies are investigating the potential of PCSK9 inhibition to reduce cardiovascular events in high-risk patient populations with unmet needs in clinical management, including those who are statin intolerant and those with familial hypercholesterolaemia.

How will your members benefit from joining the PCSK9 Forum?

The Forum offers clinicians and scientists worldwide FREE MEMBERSHIP by simply registering at our website www.pcsk9forum.org.

Registered members will have open access to electronic and multimedia platforms providing real-time reporting of significant developments and news, authoritative analyses and commentaries, and an extensive library of accredited educational materials.

Members will:

- Receive regular reviews reporting the latest developments in the rapidly evolving understanding of the biology, genetics and therapeutic potential of PCSK9, which will be tailored to the varying needs and levels of knowledge across the clinical and scientific communities.
- Gain the opportunity to interact, network and exchange information with key colleagues in basic and clinical research and in medicine who are instrumental in expanding this field via closed and open meetings at major Congresses and Symposia.
- Access authoritative, independent and peer-reviewed educational resources and tools.
- Participate in e-based Forums, Roundtables and other educational activities.
- Access research funding through educational grants which will be raised by the Forum.

How is the Forum governed?

To ensure the independence and transparency of our not-for-profit Forum, an independent Secretariat has been appointed.

The PCSK9 Education and Research Forum will be managed by an Executive Editorial Board; members of an International Advisory Board will be consulted to provide regular commentaries, feature articles on controversial topics and expert perspectives on new scientific findings and clinical developments.

Comprehensive disclosures and conflicts of interest have been deposited with the Secretariat by all Editors and Members of the Advisory Board.

The PCSK9 Education and Research Forum will apply for unrestricted educational grants from the healthcare industry as well as charities, government and non-government organisations focused on the prevention and treatment of cardiovascular disease.

In recognition of commitment to transparency and compliance with best practice, all support will be openly acknowledged and all relevant disclaimers incorporated.

The PCSK9 Education and Research Forum will be entirely independent of any influence from both the private and public sectors.

How can Israeli Atherosclerosis Society assist this global effort?

We and our colleagues who have initiated the Forum would be extremely appreciative if you could invite your members to join us in this global network through distribution of our newsletter www.pcsk9forum.org/newsletter

If the therapeutic potential of PCSK9 modulation is proven, then this will provide clinicians with the opportunity to fundamentally improve the prognosis of many high-risk patients with atherosclerotic disease. However, we will only be able to fully explore this opportunity in a global effort in which we hope the *PCSK9 Education and Research Forum* can play a part. Your support is clearly critical to the success of this initiative, and we thank you in advance for your efforts on our behalf.

Please do not hesitate to contact us if you have any questions or if you would like to discuss the Forum further.

With best regards,



M John Chapman, PhD, DSc, FESC
Editor, PCSK9 Education and Research Forum

Research Professor, University of Pierre and Marie Curie,
Director Emeritus, INSERM,
Past-President, European Atherosclerosis Society,
Pitié-Salpêtrière University Hospital,
Paris, France



Henry N Ginsberg, MD
Editor, PCSK9 Education and Research Forum

Irving Professor of Medicine,
Columbia University, New York

Secretariat: Sherborne Gibbs Limited, 3 Arrow Court, Adams Way, Springfield Business Park, Alcester, B49 6PU, UK. Tel: +44 (0)1789 766098; Fax: +44 (0)1789 768610.
email: cdeakin@sherborgibbs.co.uk

WARNING - This message and any file transmitted with it is confidential and may also be legally privileged. If you are not the intended recipient you should not copy, store or use any part of it or disclose its contents to any other person. If you have received it in error please notify us immediately. The Company does not guarantee that this message is free of viruses and does not accept liability thereof.

A stylized handwritten signature in black ink, featuring a large, bold initial 'M' followed by a series of loops and a long, sweeping horizontal stroke extending to the right.A handwritten signature in black ink, appearing to read 'Gary Kirby MS', written in a cursive style.

This Message confirms that this email message has been scanned by Bright-mail for the presence of malicious code, vandals & computer viruses.